Reassessing the Risks and Benefits of Thiopurines in Crohn's Disease

被引：0
作者：
Kinnucan, Jami A. [1 ]
Hanauer, Stephen B. [1 ]
机构：
[1] Univ Chicago, Med Ctr, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 11卷 / 04期
关键词：
INFLAMMATORY-BOWEL-DISEASE; LONG-TERM; MAINTENANCE INFLIXIMAB; WITHDRAWAL TRIAL; AZATHIOPRINE; THERAPY; 6-MERCAPTOPURINE; BLIND; LYMPHOMA; IMMUNOMODULATORS;
D O I：
10.1016/j.cgh.2012.12.022
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：395 / 397
页数：3
相关论文
共 40 条
[1]   Review article: monitoring of immunomodulators in inflammatory bowel disease [J].
Aberra, FN ;
Lichtenstein, GR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) :307-319
[2]   Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study [J].
Beaugerie, Laurent ;
Brousse, Nicole ;
Bouvier, Anne Marie ;
Colombel, Jean Frederic ;
Lemann, Marc ;
Cosnes, Jacques ;
Hebuterne, Xavier ;
Cortot, Antoine ;
Bouhnik, Yoram ;
Gendre, Jean Pierre ;
Simon, Tabassome ;
Maynadie, Marc ;
Hermine, Olivier ;
Faivre, Jean ;
Carrat, Fabrice .
LANCET, 2009, 374 (9701) :1617-1625
[3]   Safety Profile of IBD: Lymphoma Risks (Reprinted from Gastroenterology Clinics of North America, vol 38) [J].
Bewtra, Meenakshi ;
Lewis, James D. .
MEDICAL CLINICS OF NORTH AMERICA, 2010, 94 (01) :93-+
[4]   Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [J].
Bouhnik, Y ;
Lemann, M ;
Mary, JY ;
Scemama, G ;
Tai, R ;
Matuchansky, C ;
Modigliani, R ;
Rambaud, JC .
LANCET, 1996, 347 (8996) :215-219
[5]  
BROOKE BN, 1969, LANCET, V2, P612
[6]   Long-term Outcome of Patients With Crohn's Disease Who Respond to Azathioprine [J].
Camus, Marine ;
Seksik, Philippe ;
Bourrier, Anne ;
Nion-Larmurier, Isabelle ;
Sokol, Harry ;
Baumer, Philippe ;
Beaugerie, Laurent ;
Cosnes, Jacques .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) :389-394
[7]   A CONTROLLED DOUBLE-BLIND-STUDY OF AZATHIOPRINE IN THE MANAGEMENT OF CROHNS-DISEASE [J].
CANDY, S ;
WRIGHT, J ;
GERBER, M ;
ADAMS, G ;
GERIG, M ;
GOODMAN, R .
GUT, 1995, 37 (05) :674-678
[8]   Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease [J].
Chouchana, L. ;
Narjoz, C. ;
Beaune, P. ;
Loriot, M-A ;
Roblin, X. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (01) :15-36
[9]   Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].
Colombel, Jean Frederic ;
Sandborn, William J. ;
Reinisch, Walter ;
Mantzaris, Gerassimos J. ;
Kornbluth, Asher ;
Rachmilewitz, Daniel ;
Lichtiger, Simon ;
D'Haens, Geert ;
Diamond, Robert H. ;
Broussard, Delma L. ;
Tang, Kezhen L. ;
van der Woude, C. Janneke ;
Rutgeerts, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395
[10]   Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease [J].
Corken Mackey, Ann ;
Green, Lanh ;
Liang, Li-ching ;
Dinndorf, Patricia ;
Avigan, Mark .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02) :265-267
1234